[HTML][HTML] Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm

L Philippe, A Ceroi, E Bôle-Richard, A Jenvrin… - …, 2017 - ncbi.nlm.nih.gov
L Philippe, A Ceroi, E Bôle-Richard, A Jenvrin, S Biichle, S Perrin, S Limat, F Bonnefoy…
Haematologica, 2017ncbi.nlm.nih.gov
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with
a poor prognosis. No consensus regarding optimal treatment modalities is currently
available. Targeting the nuclear factor-kappa B pathway is considered a promising
approach since blastic plasmacytoid dendritic cell neoplasm has been reported to exhibit
constitutive activation of this pathway. Moreover, nuclear factor-kappa B inhibition in blastic
plasmacytoid dendritic cell neoplasm cell lines, achieved using either an experimental …
Abstract
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promising approach since blastic plasmacytoid dendritic cell neoplasm has been reported to exhibit constitutive activation of this pathway. Moreover, nuclear factor-kappa B inhibition in blastic plasmacytoid dendritic cell neoplasm cell lines, achieved using either an experimental specific inhibitor JSH23 or the clinical drug bortezomib, interferes in vitro with leukemic cell proliferation and survival. Here we extended these data by showing that primary blastic plasmacytoid dendritic cell neoplasm cells from seven patients were sensitive to bortezomib-induced cell death. We confirmed that bortezomib efficiently inhibits the phosphorylation of the RelA nuclear factor-kappa B subunit in blastic plasmacytoid dendritic cell neoplasm cell lines and primary cells from patients in vitro and in vivo in a mouse model. We then demonstrated that bortezomib can be associated with other drugs used in different chemotherapy regimens to improve its impact on leukemic cell death. Indeed, when primary blastic plasmacytoid dendritic cell neoplasm cells from a patient were grafted into mice, bortezomib treatment significantly increased the animals’ survival, and was associated with a significant decrease of circulating leukemic cells and RelA nuclear factor-kappa B subunit expression. Overall, our results provide a rationale for the use of bortezomib in combination with other chemotherapy for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm. Based on our data, a prospective clinical trial combining proteasome inhibitor with classical drugs could be envisaged.
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果